Versant Capital Management
SMMT icon

Versant Capital Management’s Summit Therapeutics SMMT Stock Holding History

Versant Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.06K Buy
+240
New +$3.59K ﹤0.01% 2483
2026
Q2 		– Sell
-831
Closed -$15.8K – 2843
2026
Q1 		$15.8K Buy
831
+821
+8,210% +$13.3K ﹤0.01% 1936
2025
Q4 		$175 Buy
+10
New +$188 ﹤0.01% 2624

Other funds holding SMMT

Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Griffin Asset Management
Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Wealth Management Partners
Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Versant Capital Management's SMMT Position: Q3 2026 in Review

Versant Capital Management opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 240 shares worth $4.06K. The stake represents ﹤0.01% of the portfolio and ranks #2483 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in SMMT as recently as Q1 2026.

Versant Capital Management first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. The position peaked at $15.8K in Q1 2026. 61 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Versant Capital Management held 240 shares of Summit Therapeutics worth $4.06K as of Q3 2026.
  • Summit Therapeutics was a new Versant Capital Management position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2483 holding.
  • Versant Capital Management first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Versant Capital Management's Summit Therapeutics position peaked at $15.8K in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.